Kingswood Wealth Advisors LLC Buys New Shares in Hims & Hers Health, Inc. $HIMS

Kingswood Wealth Advisors LLC bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 2nd quarter, Holdings Channel reports. The firm bought 4,837 shares of the company’s stock, valued at approximately $241,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health in the first quarter valued at about $30,000. UMB Bank n.a. lifted its position in shares of Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock valued at $39,000 after acquiring an additional 933 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Hims & Hers Health in the first quarter valued at about $41,000. Larson Financial Group LLC lifted its position in shares of Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock valued at $42,000 after acquiring an additional 458 shares in the last quarter. Finally, Webster Bank N. A. lifted its position in shares of Hims & Hers Health by 229.1% in the second quarter. Webster Bank N. A. now owns 905 shares of the company’s stock valued at $45,000 after acquiring an additional 630 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on HIMS shares. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. UBS Group set a $30.00 price objective on Hims & Hers Health in a research report on Monday, June 23rd. Zacks Research downgraded Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a report on Saturday, September 27th. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Reduce” and a consensus target price of $38.92.

Insider Activity at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $506,060.50. Following the transaction, the insider owned 169,940 shares of the company’s stock, valued at approximately $8,581,970. This represents a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Michael Chi sold 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $56.52, for a total value of $118,692.00. Following the transaction, the insider directly owned 291,439 shares in the company, valued at approximately $16,472,132.28. This represents a 0.72% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,622,741 shares of company stock valued at $83,695,469 over the last ninety days. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Trading Down 7.3%

Shares of NYSE HIMS opened at $53.98 on Friday. The business’s 50 day moving average is $50.86 and its two-hundred day moving average is $48.00. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. Hims & Hers Health, Inc. has a 1-year low of $17.36 and a 1-year high of $72.98. The stock has a market capitalization of $12.20 billion, a P/E ratio of 67.48, a PEG ratio of 3.64 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same period in the previous year, the firm earned $0.06 earnings per share. The company’s revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.